Rates of hypoglycemia in users of sulfonylureas
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Objective To identify the demographic and clinical characteristics of sulfonylurea users. To assess the risk of hypoglycemia in patients treated with sulfonylureas in clinical practice, and to characterize the risk in relation to the different drugs used.Research design and methods A cohort of 33,243 sulfonylurea users chosen from 719 clinical practices in the United Kingdom were identified through the VAMP-Research database. Information on demographic characteristics, medical diagnoses and use of medical services was obtained through the computerized records. For a stratified sample of 500 patients, general practioners completed a structured questionnaire on the duration, treatment, and complications of diabetes mellitus, obesity, alcohol use, and smoking history. Patients with a diagnosis of hypoglycemia, as recorded in the database within a time-window of a sulfonylurea prescription, were identified. Incidence rates per person-year of sulfonylurea therapy were estimated.Results Other than a longer duration of diabetes in users of chlorpropamide, no differences were observed among users of different sulfonylurea agents with respect to diabetic complications, adequacy of diabetic control, obesity, smoking, and excessive alcohol consumption. A diagnosis of hypoglycemia during sulfonylurea therapy was recorded in 605 people over 34,052 person-years of sulfonylurea therapy, which converted into an annual risk of 1.8%. The risk in glibenclamide users was higher than in users of other types of sulfonylureas uses. Duration of therapy, concomitant use of insulin, sulfonylurea-potentiating or antagonizing and concomitant use of beta-blockers were predictive of the risk of developing hypoglycemia.Discussion Drug use patterns showed comparability among users of different sulfonylurea agents. Our findings suggest that the rate of diagnosis of hypoglycemia made by physicians is higher for glibenclamide than for other sulfonylureas. An epidemiological study with objectively diagnosed hypoglycemia should be undertaken to confirm these results.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the weight gain attributed to the anabolic effects of increased insulin secretion, the main side effect of SUs is hypoglycemia307, 308 due to excess circulating insulin levels and due to the fact that SUs evoke insulin secretion in a glucose-independent manner.309”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [308]
In the citing paper
“Rates of hypoglycemia are higher especially for glibenclamid than for other sulfonylureas [ 58 ].”
From Hypoglycemia Unawareness—A Review on Pathophysiology and Clinical Implications (2024) · cites this paper as [58]
Citations
Cites
Epidemiologic Research: Principles and Quantitative Methods.
Mayer, L. S., Kleinbaum, D. G., Kupper, L. L., & Morgenstern, H. (1984) · Journal of the American Statistical Association · doi:10.2307/2288427 · Cited by 2,905
Jick, H., Jick, S. S., & Derby, L. E. (1991) · BMJ · doi:10.1136/bmj.302.6779.766 · Cited by 839
Drug Facts and Comparisons 1991.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-823_1 · Cited by 776
(1985) · Cited by 487
USE OF POISSON REGRESSION MODELS IN ESTIMATING INCIDENCE RATES AND RATIOS
FROME, E. L., & CHECKOWAY, H. (1985) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114001 · Cited by 396
Jick, H., Terris, B. Z., Derby, L. E., & Jick, S. S. (1992) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2630010607 · Cited by 265
Drug-Induced Hypoglycemia: A Review of 1418 Cases
Seltzer, H. S. (1989) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30395-5 · Cited by 262
Glibenclamide-associated hypoglycaemia: A report on 57 cases
Asplund, K., Wiholm, B.-E., & Lithner, F. (1983) · Diabetologia · doi:10.1007/bf00257338 · Cited by 256
Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research
Yola, M., & Lucien, A. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90170-8 · Cited by 253
Berenice, S. M. (1951) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/8.5.377a · Cited by 218
Research works printed but not linked: 5
- Berger, 1986, Die relative Haeufigkeit der schweren Sulphonylharnstoff-Hypoglykaemie in den letzen 25 Jahren in der Schweiz, Schweiz Med Wochenschr, 116, 145
- 1983, Multicentre study: UK prospective study of therapies of maturity onset diabetes, Diabetologica, 24, 404
- Hall, 1988, Postmarketing surveillance using a computerized general data base, Pharmaceut Med, 2, 345
- Hellman, 1984, Glibenclamide is exceptional among hypoglycaemia agents in accumulating progressively in B-cell rich pancreatic islets, Br J Pharmacol, 82, 689
- Seltzer, 1972, Drug-induced hypoglycemia: A report of 57 cases, Diabetes, 21, 955, 10.2337/diab.21.9.955 · DOI · Paper page
Cited by
Type 2 Diabetes Mellitus: A Review of Current Trends
Olokoba, A. B., Obateru, O. A., & Olokoba, L. B. (2012) · Oman Medical Journal · doi:10.5001/omj.2012.68 · Cited by 1,338
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
Hypoglycaemia in Type 2 diabetes
Amiel, S. A., Dixon, T., Mann, R., & Jameson, K. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02341.x · Cited by 472
Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms
Xu, L., Li, Y., Dai, Y., & Peng, J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.015 · Cited by 452
Metadata
- Authors
- Van Staa, T., Abenhaim, L., & Monette, J.
- Affiliations
- Jewish General Hospital (CA)
- ORCID
- Abenhaim, Lucien
- Venue
- Journal of Clinical Epidemiology
- Publisher
- Elsevier BV
- Published
- 1997-06
- Volume
- 50
- Issue
- 6
- Pages
- 735-741
- ISSN
- 0895-4356 (ISSN-L)
- OpenAlex
- W2164584957
- Cited by
- 211
- References
- 25
- Citations by year
- 2025: 3 · 2024: 7 · 2023: 8 · 2022: 7 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 8 · 2017: 11 · 2016: 10 · 2015: 14 · 2014: 14 · 2013: 7 · 2012: 14
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Clinical Epidemiology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- sulfonylureas, hypoglycemia, glibenclamide, chlorpropamide, diabetes mellitus, hypoglycemia incidence, risk factors, beta-blockers, treatment duration, real-world drug use
- MeSH terms
- Adult, Aged, Chlorpropamide, Female, Glyburide, Gliclazide, Glipizide, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Surveys and Questionnaires, Risk, Risk Factors, Sulfonylurea Compounds, Time Factors, Tolbutamide, Incidence, Poisson Distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rates of hypoglycemia in users of sulfonylureas. https://app.cochat.ai/papers/10.1016/s0895-4356(97)00024-3
- The paper
- Van Staa, T., Abenhaim, L., & Monette, J. (1997). Rates of hypoglycemia in users of sulfonylureas. Journal of Clinical Epidemiology. https://doi.org/10.1016/s0895-4356(97)00024-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.